Navigation Links
AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Date:11/12/2010

REDWOOD CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

Piper Jaffray & Co. is acting as sole book-running manager. Canaccord Genuity Inc., Cowen and Company, LLC and JMP Securities are acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, Telephone 1-800-747-3924.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... DIEGO , Jan. 24, 2017 ... in clinical materials management services, is pleased to ... of Operations. Kevin joins the Sherpa team to ... the highest level of service excellence. ... chain and pharmaceutical manufacturing industries. He has extensive ...
(Date:1/24/2017)... BERWYN, Pa. , Jan. 24, 2017 /PRNewswire/ ... Phase 2 biopharmaceutical company developing novel therapies for ... diseases, today announced the appointment of four world-class ... (SAB). These new appointments join QR Pharma,s previous ... strategic leadership and direction to support the development ...
(Date:1/24/2017)... FRANCISCO , January 24, 2017 The global  ... USD 239.8 billion by 2025, based on a new report by Grand ... cancer is projected to drive the market over the forecast period. Advancements ... are also estimated to boost growth.  Continue ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... of a new report from the Frank Hawkins Kenan Institute of Private ... business leaders, academics and policy makers identified concrete solutions at the “What’s Next, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The NewKILO JRP, a ... (NMIs) and co-funded by the European Union (EU), was completed in May 2015. The ... instead being maintained and used in air, which presents some challenges to establishing traceability ...
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... ... ... “Who Would Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into ... purpose in her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation ... writing. , Sharon shares that she started her spiritual journey later in life, ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... by patient survivors, today announced formation of its first global advisory board ... initiatives. , Like HCP founders, the global advisory board is composed ...
Breaking Medicine News(10 mins):